Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
microRNA
57%
Diseases
38%
Neoplasm
31%
Chitosan
28%
Doxorubicin
26%
Diabetes Mellitus
24%
Drug Delivery System
24%
Warfarin
23%
Liver Cell Carcinoma
21%
Polysaccharide
17%
Rat
17%
Hyaluronic Acid
15%
Silymarin
14%
Nanoparticle
13%
SARS Coronavirus
13%
Clopidogrel
13%
Liver Enzyme
13%
Silibinin
13%
Cisplatin
13%
Prostate Cancer
13%
Liposome
13%
Astragalus
13%
Breast Cancer
13%
Antioxidant
12%
Untranslated RNA
12%
Tablet
12%
Nanomaterial
12%
Cardiovascular Disease
11%
Biological Marker
11%
Tumor Growth
10%
Chemotherapy Regimen
10%
Biocompatibility
10%
Lung Cancer
10%
Carbon Dioxide
10%
Quercetin
10%
Cardiotoxicity
10%
Resveratrol
10%
Hemoglobin A1c
10%
Apigenin
10%
Absorption-Distribution-Metabolism-Excretion Toxicity
10%
Adverse Effect
9%
Superoxide Dismutase
9%
Combination Therapy
9%
CYP2C9
8%
Pharmacokinetic
8%
Antiinfective Agent
8%
Controlled Release
8%
Carcinogenesis
8%
High Performance Liquid Chromatography
8%
Biochemistry, Genetics and Molecular Biology
MicroRNA
36%
Cancer Cell
14%
Programmed Cell Death
14%
Genotyping
13%
Non-Coding RNA
13%
CYP2C9
13%
Aptamer
13%
Retinitis pigmentosa
13%
Anticancer
11%
Vitamin K Epoxide Reductase
10%
RNA
9%
Tumor Progression
9%
Autophagy
8%
Adeno Associated Virus
8%
Carcinogenesis
7%
Stem Cell
7%
Osmoregulation
6%
Mugil cephalus
6%
Phase I Trials
6%
Genetic Risk
6%
Virus Gene
6%
MERTK
6%
Gene Vector
6%
JAK-STAT Signaling
6%
Single Nucleotide Polymorphism
6%
Comorbidity
6%
Gene Polymorphism
6%
Oxidoreductase
6%
Reductase
6%
Myeloid
6%
Cohort Study
6%
Indel
6%
Angiotensin-Converting Enzyme
6%
Kexin
6%
Subtilisin
6%
Proprotein Convertase
6%
Allele
6%
Drug Resistance
5%
Isoform
5%
Physiological Process
5%
Mesenchymal-Epithelial Transition
5%
Medicine and Dentistry
Breast Cancer
16%
microRNA
16%
Malignant Neoplasm
15%
Lung Cancer
13%
Systematic Review
13%
Neoplasm
11%
Cancer Cell
11%
Cancer Therapy
11%
Ophthalmology
10%
Retinitis pigmentosa
10%
Doxorubicin
10%
Programmed Cell Death
9%
Metastatic Carcinoma
9%
Adeno-Associated Virus
7%
Cancer Inhibition
7%
Hepatocellular Carcinoma
6%
Exosome
6%
Epithelial Mesenchymal Transition
6%
Prostate Cancer
6%
Gene Vector
6%
Virus Gene
6%
Subretinal Drug Administration
6%
Phase I Trials
6%
Gene Therapy
6%
Restylane
6%
Meta-Analysis
6%
Apigenin
6%
Glycon
6%
Drug Therapy
6%
Ophthalmomyiasis
6%
Silymarin
6%
Plant Extract
6%
Visual Acuity
5%
Diabetes Mellitus
5%
Combination Therapy
5%
Tumor Progression
5%
Injection
5%